Products Description
Cost-Effective PVC/PVDC High-Barrier Film for Global Pharmaceutical Export Packaging
The global pharmaceutical export market operates on a simple yet demanding principle: deliver stable, intact medication to diverse destinations, often thousands of miles away, at a competitive landed cost. For decades, manufacturers faced a difficult trade-off-either invest in premium, costly materials or risk barrier performance and product stability.
Our Cost-Effective PVC/PVDC High-Barrier Film is engineered specifically to resolve this dilemma. It delivers the essential moisture and oxygen barrier required for international transit and shelf stability, formulated and manufactured with an uncompromising focus on production efficiency, material yield, and supply chain affordability. This is not a "budget" film. It is a strategically optimized film that strips away unnecessary cost premiums while retaining the critical performance attributes required for regulatory compliance and patient safety. It is the intelligent choice for high-volume, price-sensitive markets and manufacturers seeking to expand global reach without expanding packaging budgets.
Export-Driven Design Philosophy
This film was conceived from the ground up with the exporter's P&L in mind:
Specification Rationalization: We meticulously analyzed the performance thresholds of hundreds of successful international drug stability filings. By identifying the true "safety zone" of barrier requirements-not the over-engineered maximums-we formulated a film that consistently meets and slightly exceeds regulatory benchmarks without paying for unused performance capacity.
Manufacturing Efficiency Pass-Through: Our production lines are configured for long, uninterrupted runs of this standardized grade. Economies of scale, rapid changeover protocols, and high-yield processes translate directly into lower per-kilogram costs, passed fully to our customers.
Logistics-Optimized Format: Standardized roll dimensions, core sizes, and packaging configurations minimize freight volume and simplify customs clearance documentation, reducing non-material costs associated with international procurement.
Supply Chain Certainty for Volatile Markets
Global pharmaceutical supply chains face raw material volatility, transportation bottlenecks, and currency fluctuations. Our response is structural:
Dual-Sourced Raw Materials: All critical polymers and plasticizers are qualified from at least two independent, geographically separate suppliers.
Strategic Buffer Stock: We maintain 3 months of finished goods inventory for this grade at our central warehouse, insulated from production scheduling fluctuations.
Price Stability Commitment: For contracted annual volumes, we offer price protection mechanisms, shielding you from raw material index spikes during the contract period.
Packaging Integrity Without Over-Engineering
Excessive barrier performance is invisible to the patient and irrelevant to stability if the baseline requirement is met. Our film is calibrated to the "sweet spot":
Sufficient for 36-Month Shelf Life: Demonstrated stability for the vast majority of solid oral dosage forms.
Sufficient for Global Distribution: Proven performance across all ICH climatic zones.
Sufficient for Regulatory Approval: Accepted by stringent authorities worldwide.
Not Sufficient to Waste Money: No expensive, unnecessary additive packages or exotic polymers that inflate cost without clinical benefit.
Technical Specifications: Fit-for-Purpose, Verified Performance
| Parameter | Specification | Test Method |
|---|---|---|
| Total Thickness | 250µm ± 6% (200µm, 300µm options) | Micrometer, ASTM D374 |
| PVC Substrate | Pharmaceutical-grade, non-phthalate stabilized | USP <661> |
| PVDC Coating Weight | 40 g/m² ± 4 g/m² (standard export grade) | Gravimetric, FTIR |
| WVTR (23°C, 90% RH) | ≤ 0.65 g/m²/24h | ASTM F1249 |
| OTR (23°C, 0% RH) | ≤ 7.0 cm³/m²/24h/atm | ASTM D3985 |
| Tensile Strength (MD) | ≥ 45 N/15mm | ISO 527-3 |
| Elongation at Break | ≥ 140% | ISO 527-3 |
| Seal Initiation Temperature | 130°C ± 10°C | Gradient Bar Method |
| Haze | ≤ 4.5% | ASTM D1003 |
| Shelf Life (unopened) | 24 months | Real-time stability |
Performance Verification for Export Climates:
Stability Under ICH Zone III/IV Conditions: Validated performance at 30°C/65% RH and 30°C/75% RH for 12 months with <15% WVTR degradation.
Cold Chain Resilience: Retains flexibility and seal integrity after 7 days at -10°C.
Thermal Cycling Resistance: 10 cycles of 25°C ↔ 45°C, 80% RH, shows no delamination or barrier loss.
Target Applications & Market Segments
| Segment | Application Need | Our Solution Advantage |
|---|---|---|
| Generic Pharmaceutical Exporters | Reliable, affordable primary packaging for global tender submissions | WHO-prequalification compatible; cost structure supports competitive bidding |
| CDMOs serving Emerging Markets | One film specification that works across multiple client products and destinations | Broad regulatory acceptance; predictable processing; reduces client qualification complexity |
| OTC & Supplement Manufacturers | Cost-sensitive, high-volume production with adequate barrier for non-critical actives | Excellent value-to-performance ratio; stable supply for continuous production |
| Governments & Health Ministries | Local blistering of essential medicines | Economical; reliable; established track record in public health supply chains |
| Veterinary Pharmaceutical Exporters | Adequate protection with lean cost structure for animal health products | Same GMP manufacturing standards; no regulatory premium for non-human applications |
Strategic Advantages for Global Exporters
Predictable Regulatory Acceptance Across Markets
Our film's formulation is harmonized with major pharmacopoeial expectations, not optimized for a single jurisdiction. It has been successfully referenced in drug applications filed with:
US FDA: DMF Type IV referenced; meets USP <661> Plastic Packaging requirements.
EMA: CEP available; compliant with EP 3.1.11 materials.
WHO/Prequalification: Successfully used in PQ-listed products for UN procurement.
ASEAN, GCC, ANVISA, SAHPRA: Extensive history of acceptance in emerging markets without additional local testing burdens.
This broad acceptance reduces your regulatory uncertainty and shortens the timeline for new market entries.
True Total Cost of Ownership (TCO) Advantage
The value proposition extends far below the invoice line:
Lower Rejection Rates: Consistent gauge and forming behavior reduce blister line rejects by an average of 2-3% compared to variable-cost alternative films.
Reduced Stability Study Burden: With a predictable, established performance profile, some customers have successfully bridged stability data, reducing the need for full 36-month studies on minor formulation changes.
Inventory Efficiency: Readily available from regional stock points in Asia, Europe, and the Americas, enabling just-in-time ordering and reducing your working capital tied to safety stock.
Optimized for High-Volume, High-Speed Production
This film is engineered to run lean:
Faster Line Speeds: Consistent coefficient of friction and thermal conductivity support stable operation at speeds exceeding 400 blisters per minute on modern rotary machines.
Wider Forming Windows: ±15°C tolerance in forming temperature reduces sensitivity to heater fluctuations and operator variance, improving first-pass yield.
Lower Scrap Generation: Predictable sag and reduced web breaks translate to less material waste-both the film itself and the expensive lidding foil it carries.
Extended Frequently Asked Questions (FAQ)
Q1: We currently use a 300µm film from our existing supplier. You recommend 250µm for cost savings. Is this a true apples-to-apples comparison, or are we losing protection?
A: This is the most common question we receive, and the answer lies in understanding where protection comes from. Barrier performance is primarily a function of the PVDC coating, not the PVC thickness. Our 250µm film carries a 40 g/m² PVDC coating-equivalent or higher than many 300µm films on the market. The PVC thickness contributes to mechanical stiffness and deep-draw capability, not moisture or oxygen barrier. For 80% of standard tablet and capsule applications, 250µm provides ample rigidity and robust cavity formation. We can conduct a simple "thumb test" comparison with samples: press on a formed blister of both films. If you cannot feel a meaningful difference in resistance, your patients won't either, and you are paying for unnecessary plastic.
Q2: We export primarily to Africa and Southeast Asia, where humidity often exceeds 80% in warehouses. Is this film suitable for those conditions?
A: Yes, with appropriate secondary packaging. Our film's WVTR of ≤0.65 g/m²/24h provides substantial protection. However, in non-air-conditioned warehouses with sustained >80% RH conditions, we recommend the use of an aluminum-aluminum cold form foil as the lidding, or an overwrap. This is not a limitation of our film-it applies to all standard PVC/PVDC structures under extreme prolonged humidity. For manufacturers seeking to eliminate secondary packaging, we offer our Tropical-Grade PVDC Film variant with WVTR ≤0.45 g/m²/24h. Please inquire for a separate quotation.
Q3: Our blister machines are older models, some dating to the 1990s. Will this film run reliably on legacy equipment?
A: Yes, and often better than newer films designed for high-speed rotary machines. Our film's wider forming window (±15°C) is deliberately engineered to accommodate older machines with less precise temperature control. The formulation retains good "hot strength" to prevent sagging and web breaks at the slower line speeds typical of legacy flat-plate presses. We have extensive experience supporting manufacturers in CIS countries, the Indian subcontinent, and Latin America with older equipment. We will request your machine make and model during sampling to provide pre-validated parameter recommendations.
Q4: What is the minimum order quantity for this film? We are a small generic exporter with variable demand.
A: Our standard MOQ is 1,500 kg per order. However, we recognize that emerging exporters and contract manufacturers require flexibility. We offer a Starter Consignment Program for qualified customers:
First order: 500 kg minimum.
Full MOQ applies to subsequent orders.
Available for customers with a confirmed purchase order or valid stability study protocol referencing our film.
This allows you to conduct stability studies, qualify the material, and initiate small commercial batches without over-committing inventory capital.
Q5: We need to register our product in a new market and require a CEP or DMF letter of access. Is this available for your cost-effective grade?
A: Yes, this film is fully supported for regulatory filings. We maintain a Type IV Drug Master File with the FDA and a CEP with the EDQM for this specific grade-not just a generic reference to our product family. When you request a Letter of Access, it explicitly references the exact formulation and manufacturing site of this film. There is no "regulatory discount" for choosing our cost-optimized product. We provide the same high-quality regulatory documentation as our premium grades, at no additional charge.
Hot Tags: cost-effective pvc/pvdc high-barrier film for global pharmaceutical export packaging, China, manufacturers, suppliers, factory, customized, custom, wholesale, low price, free sample
